PROCATEROL HYDROCHLORIDE HEMIHYDRATE

Possibly Marketed Outside US

Details

Stereochemistry	RACEMIC
Molecular Formula	2C16H22N2O3.2ClH.H2O
Molecular Weight	671.652
Optical Activity	( + / - )
Defined Stereocenters	4 / 4
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure of PROCATEROL HYDROCHLORIDE HEMIHYDRATE

Structure Search

SMILES

O.Cl.Cl.CC[C@@H](NC(C)C)[C@@H](O)C1=CC=C(O)C2=C1C=CC(=O)N2.CC[C@@H](NC(C)C)[C@@H](O)C3=C4C=CC(=O)NC4=C(O)C=C3

InChI

InChIKey=RZKAQAPBCFPJTK-GOPHCVLGSA-N

InChI=1S/2C16H22N2O3.2ClH.H2O/c2*1-4-12(17-9(2)3)16(21)11-5-7-13(19)15-10(11)6-8-14(20)18-15;;;/h2*5-9,12,16-17,19,21H,4H2,1-3H3,(H,18,20);2*1H;1H2/t2*12-,16+;;;/m11.../s1

HIDE SMILES / InChI

Molecular Formula	H2O
Molecular Weight	18.0153
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Molecular Formula	C16H22N2O3
Molecular Weight	290.3575
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Molecular Formula	ClH
Molecular Weight	36.461
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugbank.ca/drugs/DB01366
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/894683

Procaterol is a beta2-adrenoreceptor agonist. It is a bronchodilator that may be administered orally or by aerosol inhalation for the treatment of dyspnea caused by bronchial asthma, chronic bronchitis, and pulmonary emphysema. The drug is not approved in the USA, but is available in Japan, Indonesia, and other countries worldwide.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Beta-2 adrenergic receptor 209 Target ID: P07550\|\|\|Q53GA6\|\|\|Q9UCZ3 Gene ID: 154.0 Gene Symbol: ADRB2 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/894683	Agonist 2752

Conditions

Condition	Modality	Highest Phase	Product
Bronchial asthma 50 Sources: http://www.otsuka.co.id/en/product/detail/6/8/meptin	Primary	Approved 8583	MEPTIN Approved Use For the treatment of dyspnea caused by bronchial asthma, chronic bronchitis, and pulmonary emphysema
Chronic bronchitis 52 Sources: http://www.otsuka.co.id/en/product/detail/6/8/meptin	Primary	Approved 8583	MEPTIN Approved Use For the treatment of dyspnea caused by bronchial asthma, chronic bronchitis, and pulmonary emphysema.
Pulmonary emphysema 6 Sources: http://www.otsuka.co.id/en/product/detail/6/8/meptin	Primary	Approved 8583	MEPTIN Approved Use For the treatment of dyspnea caused by bronchial asthma, chronic bronchitis, and pulmonary emphysema.

C_max

Value	Dose	Analyte	Population
113 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	25 μg single, oral dose: 25 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
205 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
233 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
276 pg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	100 μg single, oral dose: 100 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
518 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	25 μg single, oral dose: 25 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1100 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1380 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
1590 pg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	100 μg single, oral dose: 100 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
3.1 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	25 μg single, oral dose: 25 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	50 μg single, oral dose: 50 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.7 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	75 μg single, oral dose: 75 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/1467453/	100 μg single, oral dose: 100 μg route of administration: Oral experiment type: SINGLE co-administered:	PROCATEROL plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
0.05 mg single, oral Studied dose Dose: 0.05 mg Route: oral Route: single Dose: 0.05 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/	Disc. AE: Headache, Nausea... AEs leading to discontinuation/dose reduction: Headache (grade 3, 1 pt) Nausea (1 pt) Syncope (1 pt) Syncope (1 pt) Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/
0.1 mg 2 times / day multiple, respiratory Studied dose Dose: 0.1 mg, 2 times / day Route: respiratory Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/	Disc. AE: Tremor... Other AEs: Polyuria, Nervousness... AEs leading to discontinuation/dose reduction: Tremor Other AEs: Polyuria (7%) Nervousness Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/

AEs

AE	Significance	Dose	Population
Nausea	1 pt Disc. AE	0.05 mg single, oral Studied dose Dose: 0.05 mg Route: oral Route: single Dose: 0.05 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/
Syncope	1 pt Disc. AE	0.05 mg single, oral Studied dose Dose: 0.05 mg Route: oral Route: single Dose: 0.05 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/
Syncope	1 pt Disc. AE	0.05 mg single, oral Studied dose Dose: 0.05 mg Route: oral Route: single Dose: 0.05 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/
Headache	grade 3, 1 pt Disc. AE	0.05 mg single, oral Studied dose Dose: 0.05 mg Route: oral Route: single Dose: 0.05 mg Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: unknown Food Status: FED Sources: https://pubmed.ncbi.nlm.nih.gov/2862893/
Nervousness		0.1 mg 2 times / day multiple, respiratory Studied dose Dose: 0.1 mg, 2 times / day Route: respiratory Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/
Polyuria	7%	0.1 mg 2 times / day multiple, respiratory Studied dose Dose: 0.1 mg, 2 times / day Route: respiratory Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/
Tremor	Disc. AE	0.1 mg 2 times / day multiple, respiratory Studied dose Dose: 0.1 mg, 2 times / day Route: respiratory Route: multiple Dose: 0.1 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/	unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/2861219/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
substrate 1946

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
	OCT2 434 OCT1 393 UGT 219

Drug as victim

Target	Modality	Activity
UGT 219	substrate 4014 Sources: https://www.info.pmda.go.jp/go/interview/1/180078_2259004D1047_1_009_1F.pdf Page: 36.0	major
CYP3A4 1946	substrate 4014 Sources: https://www.info.pmda.go.jp/go/interview/1/180078_2259004D1047_1_009_1F.pdf Page: 36.0	minor
OCT1 393	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1Njg1IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2MDUxOSJ9fQ==	yes
OCT2 434	substrate 4014 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDE2MDUxOSJ9fQ==	yes

PubMed

Title	Date	PubMed
The selectivity of beta-adrenoceptor agonists at human beta1-, beta2- and beta3-adrenoceptors.	2010-07	20590599
Interactions between theophylline and salbutamol on cytokine release in human monocytes.	2010-07	20388727
Functional and molecular characterization of beta-adrenoceptors in the internal anal sphincter.	2003-05	12606629
Beta2-adrenoceptors on the glial cells mediate the induction of interleukin-1beta mRNA in the rat brain.	1997-10-03	9387890
Beta 3-adrenergic receptor-mediated lipolysis and oxygen consumption in brown adipocytes from cynomolgus monkeys.	1997-02	9024225
A comparison of oral procaterol and albuterol in reversible airflow obstruction.	1988-12	2974263
Procaterol and terbutaline in bronchial asthma. A double-blind, placebo-controlled, cross-over study.	1985-10	2933998

Patents

Sample Use Guides

In Vivo Use Guide

Meptin tablets: the usual adult dose is 50 µg (one tablet) once before bed or twice daily (in the morning and before bed) by the oral route. Meptin air: in general, for adults, inhale 2 puffs (20 mcg of active ingredient) at a time, and for children, inhale 1 puff (10 mcg of active ingredient) at a time. The dosage may be adjusted according to your disease, age, or symptoms. Strictly follow the instructed dosing schedule. The maximum dosage is restricted to 4 times daily (8 puffs for adults and 4 puffs for children).

Route of Administration: Other

In Vitro Use Guide

To study the beta2-blocking activity of procaterol, a guinea pig tracheal test was performed. The trachea was excised from male guinea pigs. A spiral section of the trachea was prepared and suspended in a 30-ml tissue bath. The condition of the tracheal muscle was monitored by isometric recordings using force transducers. Phentolamine was added to the bath fluid 15 min before induction of contraction with the test compound to block alpha-adrenergic receptors. ED50 for procaterol was 11 nM.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:48:38 GMT 2025` Edited by `admin` on `Mon Mar 31 17:48:38 GMT 2025`
Record UNII	8404I5HKFJ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

PROCATEROL HYDROCHLORIDE HYDRATE

Preferred Name

English

PROCATEROL HYDROCHLORIDE HEMIHYDRATE

Common Name

English

Procaterol hydrochloride hemihydrate [WHO-DD]

Common Name

English

2(1H)-QUINOLINONE, 8-HYDROXY-5-((1R,2S)-1-HYDROXY-2-((1-METHYLETHYL)AMINO)BUTYL)-, HYDROCHLORIDE, HYDRATE (2:2:1), REL-

Common Name

English

PROCATEROL HYDROCHLORIDE HYDRATE [JAN]

Common Name

English

PROCATEROL HYDROCHLORIDE HEMIHYDRATE [MI]

Common Name

English

Code System Code Type Description

SMS_ID

100000145103